prostate cancer

Astellas Launches Xtandi in the UK
Yahoo/Zacks
Sat, 07/13/13 - 11:42 am
Astellas
Xtandi
prostate cancer
GTX Incorporated: Its 'Other' Drug, Capesaris
Seeking Alpha
Sat, 07/6/13 - 11:52 am
GTx
Capesaris
prostate cancer
Breaking Down Dendreon's European Recommendation
Motley Fool
Mon, 07/1/13 - 01:06 pm
Provenge
Europe
Dendreon
prostate cancer
Dendreon Surges After Cancer Drug Gets European Backing
Bloomberg
Fri, 06/28/13 - 10:33 am
prostate cancer
Europe
Dendreon
Provenge
Why Might This Play Shake Up the Cancer-Drug Industry?
Motley Fool
Tue, 06/25/13 - 10:41 am
cancer
JNJ
M&A
Aragon
prostate cancer
Astellas' Xtandi approved in EU for prostate cancer
Pharma Times, UK
Mon, 06/24/13 - 10:50 am
Astellas
Xtandi
prostate cancer
Europe
Medivation
Medivation retreats after J&J beefs up prostate cancer slate
The Fly on the Wall
Mon, 06/17/13 - 12:37 pm
JNJ
M&A
Medivation
prostate cancer
Aragon
Zytiga
J&J to Buy Aragon Pharmaceuticals for Cancer Candidate
Bloomberg
Mon, 06/17/13 - 09:15 am
Aragon
JNJ
M&A
ARN-509
prostate cancer
3 FDA Stories You Missed This Week
Motley Fool
Sat, 06/1/13 - 12:46 pm
Merck
suvorexant
insomnia
sleep aid
hypnotics
Celgene
Abraxane
prostate cancer
Glaxo
Tafinlar
dabrafenib
melanoma
Exelixis Announces Presentation of Updated Phase 2 Data for Cabozantinib in Men with Heavily-Pretreated Metastatic Castration-Resistant Prostate Cancer
Yahoo/BusinessWire
Sat, 06/1/13 - 12:17 pm
Exelixis
cabozantinib
prostate cancer
Progenics Pharmaceuticals' Data From a Phase 1 Study of PSMA ADC Presented at ASCO 2013
Yahoo/GlobeNewsWire
Sat, 06/1/13 - 12:15 pm
Progenics Pharmaceuticals
PSMA ADC
prostate cancer
Bayer Shakes Up Prostate Cancer Market
Motley Fool
Wed, 05/29/13 - 04:50 pm
prostate cancer
Bayer
Xofigo
Bayer, Algeta Win U.S. Approval for Prostate Cancer Drug
Bloomberg
Wed, 05/15/13 - 02:51 pm
Bayer
Algeta
FDA
prostate cancer
Xofigo
Astellas forecasts big sales growth as prostate drug catches hold
Fierce Pharma
Mon, 05/13/13 - 12:27 pm
Astellas
Xtandi
Daiichi Sankyo
Japan
Takeda
prostate cancer
Aragon Pharma's ARN-509 Is No Near-Term Threat to Medivation
Yahoo/Minyanville
Tue, 04/23/13 - 03:30 pm
Medivation
Aragon
ARN-509
prostate cancer
Medivation, Astellas Pharma provide update on Phase 3 PREVAIL
Yahoo/Fly on the Wall
Mon, 04/1/13 - 10:49 am
Astellas
Medivation
metastatic castration-resistant prostate cancer
prostate cancer
Xtandi
Nymox Pharmaceutical (NYMX +3.2%) is set to close in the green today after the company provided a positive update on Phase 2 clinical trials for NX-1207
Seeking Alpha
Wed, 03/6/13 - 10:48 am
NX-1207
prostate cancer
Nymox
Tackling Cancer: Prostate Cancer's Biggest Current and Upcoming Players
Motley Fool
Wed, 03/6/13 - 09:49 am
prostate cancer
Zytiga
JNJ
Xtandi
Medivation
Astellas
Provenge
Dendreon
Jevtana
Sanofi
Medivation falls after analyst says Xtandi must overcome obstacles
The Fly on the Wall
Thu, 02/28/13 - 11:27 am
Medivation
Xtandi
prostate cancer
Johnson & Johnson's Pioneering Zytiga And Its Competitors
Seeking Alpha
Sun, 02/24/13 - 02:26 pm
Zytiga. ARN-509
Xtandi
prostate cancer
Medivation
JNJ
Astellas
Aragon
Tokai

Pages